Slade Health broadens into antibiotic compounding with mobiLIFE
Slade Health has acquired the antibiotic compounding business mobiLIFE, including the mobiLIFE compounding facility in Morisset New South Wales.
Slade Managing Director, David Slade says the purchase of mobiLIFE’s antibiotic compounding arm adds to Slade Health’s current compounding and TGA-licensed facilities.
“This is an exciting time for Slade. We are constantly looking at new and innovative ways to deliver a comprehensive compounding service and the addition of antibiotic compounding means we can offer a complete service to our customers and subsequently their patients,” he said.
Slade Health will also be the distributor for the mobiFUSER, a safe and effective at-home care infusion pump. The mobiFUSER infusion device delivers medication on a continuous basis over a specified period of time and is ideal for 24 hour intravenous antibiotics.
“The ability to supply antibiotic compounding as well as the support of an at-home care medical device provides our hospital customers with the ability to discharge patients home safely and in a timely manner,” Mr Slade said.
The purchase of mobiLIFE’s compounding business results in Slade Health being able to offer a wide range of antibiotics compounded for infusion and reflects its ongoing commitment to providing a complete range of TGA licensed sterile compounding services.
The announcement follows Slade’s acquisition of the oncology compounding business Fresenius Kabi Australia (FKA) in October 2015, including FKA’s TGA licenced compounding facilities in Queensland, New South Wales and Victoria. McBeath also recently joined Slade Health as part of Icon Group’s acquisition of McBeath Health Services.